Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00461708
Status:
COMPLETED
Last Update Posted:
2015-10-15
First Post:
2007-04-17
Brief Title:
A Study of Tarceva Erlotinib in Combination With Gemcitabine in Unresectable andor Metastatic Cancer of the Pancreas Relationship Between Skin Toxicity and Survival
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable andor Metastatic Cancer of the Pancreas Relationship Between Skin Rash and Survival
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This single arm study will evaluate the relationship between the skin toxicity of Tarceva in combination with gemcitabine and survival in patients with advanced andor metastatic pancreatic cancer All patients will receive gemcitabine 100mgm2 iv weekly Tarceva will be administered 100mg po per day The anticipated time on study treatment is until disease progression and the target sample size is 100-500 individuals
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None